Sangamo BioSciences | SGMO - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Alaunos Therapeutics USD 447K 138K 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Amgen USD 1.72B 134M 2026-06
Bayer EUR 3.96B 267M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.43M 222K 2026-03
CSL USD 1.23B 498M 2025-12
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Grifols EUR 320.45M 12.65M 2025-12
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.42B 381M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Merck USD 2.89B 219M 2026-06
Novartis USD 3.24B 101M 2026-06
Omeros USD 11.32M 2.48M 2024-09
Pfizer USD 3.41B 496M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Tectonic Therapeutic USD 6.43M 2.99M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06